drugset / Trial / NCT00434668
Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
Phase 2
Completed
99 enrolled
University Hospital, Antwerp
Sanofi · collabUniversiteit Antwerpen · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.
Timeline
- Start
- 2005-12
- Primary completion
- 2010-09
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Vinorelbine | Small molecule | — | — |